Analysis of vascular imaging parameters of wet age-related macular degeneration treated with anti-VEGF drugs and optical coherence tomography
Objective:To investigate the Vascular endothelial growth factor(VEGF)drug treatment of wet age-related macular degeneration and the vascular imaging parameters of optical coherence tomography.Methods:A total of 80 patients with monocular wet age-related macular degeneration treated in the Second People's Hospital of Xinxiang City from May 2018 to January 2023 were selected as the study objects,and were divided into control group and study group by random number table method,with 40 cases in each group.The control group was treated with arbocept and the study group was treated with leizumab.The section area and blood flow area of eye lesions were compared between the two groups before and after treatment,area of choroidal neovascularization(CNV),best corrected visual acuity(BCVA),Internal limiting membrane-retinal pigment epithelium(ILM-RPE)and Internal limiting membrane-RPEFit(ILM-RPEfit)before treatment and 1,2,and 3 months after treatment,whole-layer retinal blood flow density and choroidal capillary blood flow density of patients before treatment and 1,3 and 6 months after treatment.Results:After treatment,the lesion section area and blood flow area were significantly reduced in both groups,CNV area significantly reduced,BCVA significantly decreased,ILM-RPE and ILM-RPEfit were significantly thinner in both groups at 1,2 and 3 months after treatment(P<0.05).There were no significant differences in whole-layer retinal blood flow density and choroidal capillary blood flow density between the two groups before treatment and 1,3 and 6 months after treatment(P>0.05).Conclusion:In patients with wet age-related macular degeneration,treatment with anti-VEGF drugs can shrink the lesion,reduce the lesion blood flow,improve the affected eye vision,alleviate macular edema,and do not worsen the macular ischemia.Optical coherence tomography can be used to evaluate the efficacy of anti-VEGF drugs in patients with wet age-related macular degeneration.
NETL
NSTL
万方数据
